文献速递胸部肿瘤

老年EGFR突变阳性非小细胞肺癌患者低剂量阿法替尼治疗的药代动力学与药物基因组学分析

Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2021-11-30

这项前瞻性多中心、单臂、开放标签II期试验评估低剂量阿法替尼(30 mg/日)用于老年EGFR突变阳性NSCLC患者的疗效、生活质量和药代动力学/药物基因组学参数。客观缓解率为80.0%,疾病控制率为91.4%,中位无进展生存期和总生存期分别为15.6和29.5个月。结论认为阿法替尼起始剂量30 mg/日可能是老年患者有效且安全的选择。

要点

  • 低剂量阿法替尼30 mg/日的客观缓解率为80.0%,疾病控制率为91.4%。
  • 中位无进展生存期15.6个月,中位总生存期29.5个月。
  • 4例患者因不良事件停药,未观察到治疗相关死亡。

核心结论

  • 阿法替尼起始剂量30 mg/日可能是老年EGFR突变阳性NSCLC患者有效且安全的选择。

研究设计与样本

  • 前瞻性多中心、单臂、开放标签II期试验,计划注册35例,入组老年EGFR突变阳性NSCLC患者。
  • 主要终点为客观缓解率,阈值50%,预期75%,α=0.05,β=0.1。
  • 次要终点包括无进展生存期、总生存期、不良事件发生率、生活质量调查(FACT-L)及稳态 trough 血浆浓度。

主要发现

  • 患者中位年龄79岁。
  • 客观缓解率80.0%,疾病控制率91.4%。
  • 中位无进展生存期15.6个月,中位总生存期29.5个月。
  • 4例患者因不良事件停药,未观察到治疗相关死亡。
  • 基线及第4、8、12周生活质量无显著变化。

关键数值与推荐

  • 阿法替尼起始剂量为30 mg/日。
  • 客观缓解率80.0%,疾病控制率91.4%。
  • 中位无进展生存期15.6个月,中位总生存期29.5个月。
  • 4例因不良事件停药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: An increasing number of advanced non-small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 mg/day) use in elderly patients with NSCLC with EGFR mutation to assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters. PATIENTS AND METHODS: The primary end-point was the objective response rate (ORR), and the planned number of registered cases was 35, with a threshold ORR of 50%, an expected ORR of 75%, α of 0.05, and β of 0.1. Secondary end-points were progression-free survival (PFS), overall survival (OS), the incidence rate of adverse events (AEs), QOL survey (FACT-L), and trough plasma concentration of afatinib at steady state (Css) and at the occurrence of clinically significant AEs. RESULTS: The median age of the patients was 79 years. The ORR was 80.0% and the disease control rate was 91.4%. The median PFS and OS were 15.6 and 29.5 months, respectively. Four patients discontinued because of AEs. Treatment-related death was not observed. No significant change in QOL was observed at baseline and after 4, 8, and 12 weeks. Css was comparable with those in previous reports and was significantly higher in patients with grade 3 AEs. Direct correlations between afatinib treatment and PGx profiles were not observed. CONCLUSIONS: An afatinib starting dose of 30 mg/day could be an effective and safe treatment option for elderly patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mizugaki H, Oizumi S, Fujita Y, et al. Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. Eur J Cancer. 2021. PMID: 34862083. doi:10.1016/j.ejca.2021.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。